• The findings of the study, headed by the Breast Cancer Group at the VALL D’HEBRON ONCOLOGY INSTITUTE (VHIO) in Barcelona, present a new treatment option for patients with metastatic breast cancer.
• Eribulin is the first drug in the last 10 years to have an impact on metastatic breast cancer survival rates without having to be combined.
• The drug improves survival rates by 20% and has a very good toxicity profile compared to other chemotherapy drugs.
• The objective of the Phase III clinical trial was to identify the efficacy of a new treatment strategy for metastatic breast cancer.
VHIO researchers have found a gene associated with resistance to HER2+ breast cancer treatment which could point to a new treatment strategy to conquer this disease.
The group led by Dr Joan Seoane, ICREA Research Professor at the VHIO, has carried out the research in glioma, the most common malignant brain tumor. The study published describes how to identify cells with characteristics of stem cells in the interior of the glioma. These cells, known as Glioma initiating cells (GICs), are responsible for initiating the glioma and also for it reappearing after surgical removal.
From September, Dr Baselga combines the scientific management of the Vall d’Hebron Institute of Oncology (VHIO) with his new appointment at the Hematology & Medical Oncology Division at the Cancer Center of the Massachusetts General Hospital at Harvard Medical School in Boston.
Approximately 30% of all breast cancers currently diagnosed have a genetic abnormality
Today, we know much more about why a cell becomes cancerous and about which proteins and genes are responsible for this happening
The Vall d’Hebron Institute of Oncology (VHIO) has published a new study describing a new molecular mechanism that regulates the renewal of the glioma stem cells. The findings represent an important advancement in the research centred on one of the most aggressive brain tumours, the glioblastoma multiforme
Davide Melisi will offer a conference about TGF-ß signaling for anticancer therapies
Christopher Proud, from Southampton University, presents the latest advancements related to mTOR, involved in certain cancers
Antonio Hurtado, from the Cambridge Research Institute, will offer a seminar on the factors that cause resistance to Tamoxifen on breast cancer patients
It is the first National Agreement that includes the Academic environment, basic research, clinical research and the pharmaceutical industry
The “Olga Torres” Foundation awards to a VHIO research group a grant for the research on tumor stem cells
